Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maintaining a Sustainable Environment for Innovation: Ending the Evidence Arms Race for Regulatory and Reimbursement Decision-Making

This article was originally published in RPM Report

Executive Summary

Increasing attention on containing healthcare costs has spurred new business opportunities in data aggregation, real-time analytics, and rapid translation of data into evidence on the value of new innovation. This has become a race for more and faster evidence. But is the investment made by manufacturers, payers, and the government resulting in better evidence to aid patients and clinicians in making better decisions?

You may also be interested in...



Paying for New Drugs for New Bugs: Regulation is Only One Side of the Coin

FDA and Congress are making great strides in improving the regulatory pathway and intellectual property protection for anti-infectives. But without changes in the reimbursement process, the package of incentives may not be enough to spur innovation in the class.

Topics

UsernamePublicRestriction

Register

PS080989

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel